Objectives: In manymedicaldomainsinvestigatorinitiatedclinicaltrials are usedtointroduce new treatments andhenceact as implementationsofguidelinebasedtherapies. Trial protocols containdetailedinstructions to conduct thetherapy andadditionally specify reactionstoexceptional situations (for instance an infection or atoxicity). To increasequality in health care andraise thenumberofpatients treated according to trial protocols, aconsultation system is needed that supports thehandling of thecomplextrial therapy processes efficiently. Our objective wastodesign and evaluate aconsultation system thatshould 1) observe the statusofthe therapiescurrentlybeing applied, 2) offer automatic recognition of exceptional situations andappropriate decision support and3)provide an automatic adaptation of affected therapy processes to handleexceptional situations. Methods: We appliedahybrid approachthatcombines process support forthe timely andefficientexecutionof the therapy processesasoffered by workflow management systemswithaknowledge and rule base and a mechanism fordynamicworkflow adaptation to change running therapy processesifinducedbychanged patient condition. Resultsand Conclusions: This approach hasbeen implemented in the AdaptFlow prototype.Weperformed severalevaluation studiesonthe practicability of the approach andthe usefulnessofthe system.These studies show that theAdaptFlow prototype offers adequate support forthe execution of real-world investigator-initiated trial protocols andisable to handle alarge numberofexceptions.
Introduction
Clinical trials aret he acceptedm ethod to evaluate newt herapies in medicine [1, 2] . They allowt he compatibility andt he efficiency of newtherapies to be examinedand offerawaytocompare different treatments fort he samed isease pattern. Investigatorinitiatedm ulticenter trial treatment protocols areparticularlywidespread in hematooncology ando ftene ncompasss everal thousandpatients.Hence, althoughtheyare designedp rimarilyt op rovide answerst o scientific questionst heyo ftena lsoa ct as guidelines for physicians in manyhospitals to specifyt he treatment(s).I nG ermany about 20-50% (disease-dependent) of all newlydiagnosed patients with leukemiasor lymphomaswill be included in atrial. The protocols usuallyc ontain detailed instructionsonhow to perform diagnosis, therapy, toxicity management, andf ollow-up (see section 3).Inour institution we areresponsiblef or the biometry andc oordination of manysuchtrials.
One goal for the useofinvestigator-initiated treatment protocols is to increase the quality in health care. In ordert or aise the numbero fp atients treated according to high-quality treatment protocols andtaking part in clinical trials,aconsultation system is needed thats upports the handling of the entire complextrialtherapy processes efficiently. To supportclinicians in selecting the adequate trials andt reatments in oncology we have designedaweb-based softwaretool calledOncoWorkstation. It provides assistance in the choice,c omparison, andp lanningo fo ncologicalg uideline-based trial protocols [3] . However, the execution supportislimitedtosimple calculationsofpatient-relatedt herapy plans containing the drug applications. Despite the detailedtherapyplans,asignificantdegreeofflexibility in treatments arises through exceptional situations( e.g., an infection or at oxicity) whichmay frequentlyoccurduring therapy execution.For instance, we checked anonymous patientd ata a for ah igh dosage lymphoma protocol( MEGA-CHOEP [ 4] ) and found thatf or nearly each patienta tl east one treatment cycleh ad to be postponed mostlyd ue to acute toxicity.F urthermore, morethan11% of the patients droppedout of the trial during the treatment andf or further 11% of the patients the protocol treatment hasbeen abandoned(seeTable1).
Treatment protocols additionallycontain information about the properr eactionst o such exceptional situations. However, a specialized physicianh as to handle many different protocols for different patients at the sametime.Therefore, aconvenient consultation system should observe the status of the therapies currentlyb eing applied, offera utomatic recognition of exceptional situationsand appropriatedecision support for handling such situations. Furthermore, the system should be able to automatically adapta ffected therapy processes to adequatelyhandle the flexibility of treatment processes.
Fors ome of thesep roblems, e.g., the handling of data andk nowledge or the organization of clinical activities, there arealreadyseveral systemsinuse in the medical domain [5] [6] [7] [8] [9] [10] . But to meetall these requirements,ah ybrida pproach is necessaryt hat combines aw orkflow management system with aknowledge andrule base. Theworkflow system supports the coordination of activitiesand the integration of different users, a The data has been kindlyp rovided by the Non-Hodgkin-Lymphoma study secretariat at the Institute for Medical Informatics, Statistics and Epidemiology,UniversityofLeipzig(http;//www. lymphome.de/Gruppen/DSHNHL). data andapplications [11, 12] to ensure the timelya nd efficiente xecution of therapy processes.I ti su sed to model the therapy processes andcoordinate their execution by notifying each user (e.g., ap hysician or a nurse)intime about the next therapy steps he hast oe xecute foraparticularp atient treated according to ap articularp rotocol. The workflowsystem also provides the user with the data needed for each therapy step. Furthermore,t he workflows ystem hast o offerd ynamica daptation of therapy workflows during execution to handle the flexibility of therapy processes [13, 14] , i.e. to change running therapy processes if induced by changedp atient condition. Thus the therapy processes mayb ea dapted to a changedsituation andalwaysrepresent the appropriatetherapy for aparticularpatient. The rule base handles the medical knowledge represented in the protocols andi s used to detect exceptional situations.
Objectives
Thehybridapproach hasbeen implemented in the AdaptFlowprototype thatisbeing developed at the University of Leipzig. The main objectives of the AdaptFlowprototype are:
• observation of the status of the therapies currentlybeing applied, • an ovel ECA( Event/Condition/Action) model [15] to describe the exceptional situationsformally, • automatic recognition of exceptional situationst hatm ay require changeso f treatment, • appropriated ecision supportt od etermine the suitabletherapy changesinconsideration of the trial protocol andthe appropriatechangesofthe treatment workflow, and • automatic adaptation of affected therapy processes so thatt heyc an be executed further.
Furthermore,AdaptFlowistooffer the user the possibilityt om odifyt he therapy manuallyincase of unexpected exceptionsorif the automatically-derivedc hangesa re undesired. To coverthe complexity of different protocols,t hreer epresentativet rialp rotocols fromd ifferent oncological fields have been chosen:h igh dosage therapy used in aggressive non-Hodgkin lymphoma (MEGA-CHOEP [ 4] ), adult colon cancer therapy (InTact [16] ) andp ediatric acute myeloid leukemia therapy (AML-BFM [17] ). The focus is on protocols from oncologya st heyo ffer longr unning processes suitablef or workflowm anagement, ah igh degree of relevancea nd complexity,a nd a significant number of exceptional situations thatare describedinthe therapy protocols. Thep aper is organizeda sf ollows. Section 2discusses relatedwork. Section 3de-scribesam edical scenario foratherapy protocol before providing an exception classification andintroducing the rule model in section 4. Section 5gives an overviewofthe AdaptFlowprototype andsection 6presents the evaluation. Ad iscussion is subjecto f section 7b efore we closew ith as ummary andasketch of future work (section 8).
Related Work
Theapplication scenario forthe AdaptFlow prototype is the enhancemento fc onsultation systemsw ith workflows upportf or the execution of complete therapy processes describedi ni nvestigator-initiatedt rial protocols. Thus,AdaptFlowisnot part of a clinical information system as describedin [8] [9] [10] . However, it is suitablet oc omplement clinical information systems, especially to provide supportf or therapy processes.Itisalsonot alaboratorysystem or a calculator fort herapy plans butu ses the functionality offeredb yt hese systemst o supportt he execution of the entire therapy process. Fori nstance, data provided by chemotherapy calculation programs maybe presented to the user togetherw ith the activitiesi naprocess instancef or ac hemotherapy cycle.
AdaptFlowalsodiffers fromexpert systems fort herapy planning andm onitoring such as ONCOCIN [18] as it does not use planning techniques to iterativelycalculate the therapy plans butuses predefinedtherapyprocesses represented as workflows. To handle the inherent flexibility the workflows are dynamically adaptedi ff ailure events occur. Then ecessarym odifications arederived from the rulescontainedinthe investigator initiated trialp rotocols again without the useo fp lanning or refinement techniques from artificialintelligence.
Severalvendors andresearchershaveaddressed failurea nd exception handling in workflowm anagements ystems [19] [20] [21] [22] [23] [24] [25] or in computerized implementation of clinical guidelines [26] [27] [28] . However, onlyafew commercialw orkflow systemss ucha s [19] [20] [21] p rovide anys upportf or workflow adaptation.F or example, [21] is able to derive on the basisofECA rulesthatanadditionalactivity hastobeexecuted. However, the user hast os elect an appropriatei nsertion point in the workflowm anually. Furthermore,mostcommercial systemsdonot offerdecision supportfor the choice of the appropriatetype of exception handling.
Some research prototypes offerm anual workflowa daptations or automatic adaptation of the activity currentlyb eing executed [22] [23] [24] . Thef irsta pproach requires an expert whoh as to decide which events (e.g.l aboratoryv alues) constitute logical failures andwhich adaptationshave to be performed.However,considering the huge amount of data ap hysician is faced with, this approach can be time-consuming ande rror-prone as exceptional situations mayb ed etected too late or overlooked completely.
Thes econd approach is also onlyo f limitedusefulness as workflowparts notyet executedc annot be adapted. In oncology, this is of particular importance as thepatientspecific drugsf or ac hemotherapy have to be orderedone or twodaysbefore the plan- nedadministration. Thus,inordertoallow for the timelyadministration of drugs or to prevent an infusion fromh aving to be discarded, the corresponding workflowadaptationshouldbeperformedassoon as possible. Medical planning systems(e.g., [27, 29, 30] in oncology) offeranadequate representation of medical knowledge,b ut typically do not supportt he temporald imension of failures sufficientlya nd offero nlyl imited supportofoperationalaspects. Forinstance, workflowm odeling ande xecution is not supported efficiently. So,existing processes cannot easily be changedi ft he underlying protocols arec hanged. Furthermore,t he systemsdonot offeradvanced integration of data andusers.
Scenario
Ac ommon wayt od escribe ac hemotherapeutical therapy is to displayt he normal therapy process with its prerequisites (i.e. the conditions underw hich apatient is eligible forthe therapy andfulfills the requirements of the trial) andt he circumstances underwhich an alternativebehavior should be employedo ru nderw hich at rial-compliant treatment is no longerp ossible. An example is showninF igure 1. Chemotherapiestypicallyconsist of severalmaintherapyp rocesses (calledc ycles)i nd ifferent therapy branches( e.g., in Fig. 1C HOP21 denotesacycle).Thecycles areseparated by staging andr estaging examinations, documentation steps and additional therapeutic steps such as radio or supportive therapies. Someo ft he therapy components (e.g.t he cycles) can be decomposed into smaller partssuchasthe administrationsofdrugs or the examination of diagnostic parameters. These partsare encodedasactivitieswithin the workflowd efinition. Figure 2s hows a fragment of at herapy cyclec onsisting of five drug administration activitiesexecuted in parallel( application details have been omitted for aclearer presentation).
Oncological therapiesa re complexa nd their process maydifferfrom patienttopatient, even if theyh avet he samed isease. However, the necessity of atreatment modification foraparticularp atient oftend oes not reveal itselfuntilthe treatment is already in progress. Thec hangesa re triggered through events (exceptions) such as allergies,l ow blood counts, or unexpected disease progression requiring adaptationssuch as dosagemodifications,drugreplacements or individual supportive therapy steps. Normally the treating physicianchooses the mosta ppropriateo ut of severalm edically andeconomically feasibleand ethicallyjustifiablealternatives. Fortreatments in clinical trials,the adaptationsneeded for important andfrequentlyoccurring exceptionsare describedinthe therapy protocol.
To illustrate howat herapy workflowi s adaptedw hena ne xceptional situation arises, consider the following scenario. During the execution of some preliminary activitiesan eurological toxicity ( Event1in Fig. 2 ) andahematologicaltoxicity ( Event2 in Fig. 2 ) ared etected.H ence, the chemotherapy cannot be applied according to the workflowd efinitiona nd the workflowh as to be adaptedinthe rangesspecified in the Flow sheet for NHL-B protocol [42] .( The rectanglesrepresent the therapy steps, the labels encode the type of examination to be performed or the chemotherapy to be applied( e.g.C HOP 21). Each step is documented on appropriatec aser eport forms.) protocol. Sincee .g.V incristin is knownt o cause neurological toxicities, the activity AdministerVincristin hastobedynamically removedwhilethe execution of the other activitiesc an be continuedw ithout change. Furthermore,a ntibiotic drugs have to be administereda ftert he chemotherapy to compensatef or the hematologicalt oxicity andtoprotect the patient againstinfections. Thus,anew activity AdministerAntibiotics hast ob ea ddedt ot he therapy.T he right fragment in Figure 2shows the chemotherapyc ycle aftert he adaptationsh aveb een performed.
Exceptions and Rules
We have developed athree-step conceptfor the automatic detection of whetheratreatment adaptation is necessary, the determination of the corresponding treatment modification,a nd the adaptation of the treatment workflow.
To detectasituation thatm ay require a treatment adaptation,i ti sn ecessaryt oe stablishr ules that represent the conditions describedinthe trial protocols (seesection 3).I no rdert og ainacomprehensive overviewo fp ossiblee xceptions, we selected treatment protocols fromdifferent areas, as mentionedi ns ection 1, andi na nalyzing theseprotocols we found exceptional events thatm ay require treatment adaptations.
Threem aine vent types were identified: medical events (e.g., laboratoryo rp athologicalfindings, diagnoses or toxicological ratings), organizational events (e.g., resourcec onflicts of medical devices, changesofpatient status due to hospitalization), and social events (e.g., lossofpatient compliancefor the treatment).Each typeof eventr equires different data sources to be observed. Some medical events can be detected through oversight of the laboratoryor other clinical databases, while fori nstance protocol-dependent toxicologicalr atings require an additional system.M osto ft he events describedm ay onlyl ead to exceptionsincertain partsofthe treatment. Forinstance, al ow blood leukocyte count (ina n acceptabler ange)m ay be tolerable aftera cytostatic application phase, butnot during other treatment phases. This illustratest he need to consider intervals of temporalvalidity forexception handling.
To detecte xceptional events we usee xtendedE vent-Condition-Action (ECA) rules [ 15] that represent the conditions describedinthe treatment protocols (details in [31] ; [ 32] provides as imilara pproach for eventdetection). The rulesare of the following format:
WHEN exceptional event WITHc ondition THENt reatment adaptation VA LID-TIME time period
Thee vent-condition part (WHEN/WITH) specifiesthe eventand the conditions under whicht reatment adaptationsa re required. The action part (THEN) describest he necessaryt reatment modifications. The possiblemodifications arelistedinTable 2. The optional valid time part (VALID-TIME or VT)specifies atime periodduring which the modification should be applied.Itisdenoted eitherbyafixedtime interval or date, or by aconditional time intervalwhoseend is specifiedbyacondition that hastobesatisfied (e.g., untilt he blood value hasi mproved). This extension of ECA rulesw ith temporali nformation is especially needed to meet medical requirements formulatedin the protocols.
Thef ollowing ECA rule specifiest hat for ap atient with ac ritical blood value all applicationso fd rugV incristin should be droppedd uring the next sevend aysa nd a newbloodexamination hastobescheduled in three days (syntaxs implifiedf or better readability): WHEN newfinding forpatientP 1 WITHl eukocyte_serumc ount <1000 #/ mm³ THENd ropapplicationsofdrugVincristin forP 1 ANDadd newexamination of leukocyte_serumcount within three days VA LID-TIME during the next seven days Them odifications of medical treatments specifiedinthe THEN-partofthe rulescorrespond to workflowa daptations such as stopping or aborting at reatment workflow or delaying, adding, or deleting as ingle workflowactivity.The AdaptFlowmonitoring module (describedinsection 5.1below) translatest he medical treatment modificationsinto so-calledcontrol actions. Control actionsd escribe the workflowa daptations on the basiso fa ctivities, i.e. single workflowtasks, or whole workflows. Each control action consists of the description of the workflowadaptation andthe valid time VT as specifiedinthe ECArule. All control actionss upported by AdaptFlowa re listedi n Table2.For instance, the firstmodification in the THEN-parto ft he ECAr ule shown abovei st ranslatedi nto the control action drop (application_of_drug_Vincristin, P 1 ) @[for next 7d ays] (the '@' separates the adaptation description from the valid time part).
TheAdaptFlowPrototype
In this section we present the AdaptFlow prototype. Firstt he architecture is introduced before workflowa daptation is describedinmore detail.
5.1A rchitecture
AdaptFlowconsists of aworkflow management system,am onitoring module, an adaptation module,ap atient database and ar ule base. Figure 3s hows thesec omponents andt heir interaction fromt he detection of an eventt ot he workflowa daptations.
Them ainc omponent of AdaptFlowi s the workflowm anagement system. Wo rkflowm anagements ystems supportt he execution of clearly structured, frequently repeated processes.Theyoffer astrictseparation of application programcode from the overallprocess logic andthe integration of automatedand manualactivitiesand of data from different sources. Thus,t heyo ffer a good infrastructure for the implementation of the diagnosticand therapeuticprocesses of therapy protocols [13] andare used in the AdaptFlowprototype for the definition and execution of therapy workflows. As it is not suitabletodevelop aworkflow system from scratch (due to personnela nd time limitations) the ADEPT flex workflowm anagement system [22] is used.T he workflow model of ADEPT flex supports the specification of execution durationsf or activities andt emporald istances between activities. Furthermore,ADEPT flex provides operators for dropping andadding nodesinworkflow instances whichare calledusing aJavaAPI (Application Programming Interface).This offers the possibilityt op erformw orkflow adaptationsautomatically,which is not supported by commercialw orkflow management systemsorbythe ADEPT flex workflow system itself( onlym anuala daptations are supported).
Theworkflow system consistsofaworkfloweditor for workflowmodeling, a workflowengine for workflowexecution andseveral work listc lients as interfaces through whichthe tasks arepresented to users, such as physicians andnurses. During workflow modeling the therapy processes describedin the protocola re translatedinto aw orkflow definition, i.e.atechnicalrepresentation of the therapy.I faparticulart herapy is to be executedf or ap atient, the corresponding workflowdefinitionisinstantiatedb ygenerating aworkflow instance b .The workflow instanceisexecutedbythe workflowengine andthe tasks arepresented in the work list clients.F igure 4s hows as creenshot of an AdaptFloww ork list client duringt he execution of achemotherapy workflow. The upperp artc ontains ag raphical representation of the whole process. Thelower part showst he activitiest ob ee xecutedb yt he user with some additional information, such as the ID of the patient forwhom the activity hastobeperformed(firstcolumn), the start time point forthe activity andthe time left if it maynot be startedimmediately (sixth and seventh column).
The patient database contains patients' master data andl aboratory, clinical,a nd pathologyf indings. In our implementation it also contains database triggers to detect whethern ewly-enteredv aluesm ay constituteal ogical failuree vent. Thep atient database could also be part of an existing clinical information system or from a consultation system such as OncoWorkstation.
If acritical value is detected in the patient database, i.e. av alue outside the permitted range specifiedi nt he protocol, then the rule base containingm edical knowledge andt herapy-specifick nowledge derives whetherinfact the eventconstitutes alogical failurea nd determinest he appropriate therapy modifications. Them onitoring moduletranslatesthe therapy modifications into control actions(see section 4). Thecontrol actionsare transferred to the adaptation module whichadapts the affected workflow instances accordingly(see 5.2).
AdaptFlowu ses XML (eXtensible Markup Language)documents for the communication between its different components.X ML is aw idely-used data interchange format for whichvariouscommunication infrastructuresexist (e.g., XML-RPC whichwas used for the prototype).
In the currentversion of AdaptFlow, the rule base wasimplementedusing advanced database functionalitys ucha sd atabase triggers ands tored proceduresd ue to time limitations.
5.2W orkflowAdaptation
Thew orkflow adaptation process follows either ap redictive or ar eactivea daptation strategy.I fp ossible, workflows shouldb e adaptedp redictively,i .e. as soon as an exception is detected,inordertoinformworkflow usersintime about necessarychanges, and in particulart op repare newa ctivities (e.g., drug administrations) or cancel the preparation of deletedactivities. Predictive adaptation is possibleifthe valid time VT of acontrol action is specifiedbyafixed(absolute)dateorinterval. In this case, AdaptFlow can estimate the workflowp artP VT thatwill presumablybeexecutedduring VT andadapt it in advanceusing the ADEPT flex API functions (for instance, in the screenshot in Fig. 4the crossed-out node hasbeen dropped).
Reactivea daptation is used if the valid time VT of acontrol action is denotedbya conditional time interval( e.g., untilt he blood value hasi mproved), or if the workflowcontains conditional partssuchasconditional splits or loops.Inthis case it is generally not known in advancef or howl ong the condition will hold,a nd as ac onsequence the affected activitiesc annot be predicted. Therefore,the affected workflow instances (i.e., allw orkflow instances that arecurrentlybeing executedfor the patient denoted in the control action)are monitored as longasthe condition holds (e.g., as long as the blood leukocyte count of the patientis less than1.000 #/mm³).Before an activity is scheduled to be executed, the system checks whetheritisaffected of the control action.If this is the case thent he activity is adapted before it is executed.
Alla daptations (reactivea sw ella sp redictive)mustbeconfirmed by an authorized medical user before the modified workflow instancei sr esumed. Thus, the user can reject adaptationsi ft heya re not appropriate for aparticularpatient andperformmanual exception handling instead.
Theestimation of the workflowpartP VT during predictive adaptation is based on temporali nformation that wass pecified during workflowdefinition, such as average activity execution durations( e.g., the duration of ad rugi nfusion) or temporald istances between twoactivities(e.g., to specify aw aiting time between twodrugapplicationsorexaminations). To estimate P VT of an affected workflowinstancethe execution durationsofall paths through the remaining workfloware estimated, starting with the activitiest hatw ill be executedn ext( for instance the activitiesw ith an attached playbutton in Fig. 4 ). This is done by estimating anda dding together the durations of the workflowc onstructs (i.e., sequences, split/ join-blocks or loops)apath consists of. Estimation of apathstopsifthe valid time interval is "consumed" by thatpathorifthere arei rresolvable conditions at OR-SPLIT nodeso rl oops.P VT thenc onsists of all nodesa nd edgeso ft he estimatedp aths whicha re assumedt ob ee xecutedd uring VT.Amored etailedd escriptiono fw orkflow estimation can be found in [31] .
Evaluation
Fora ne valuation of the AdaptFlowp rototype we have chosen athree-step approach. First, we modeled the three protocols named in section 1i nAdaptFlowt ot est the functionality of the system.Inasecondstepwe analyzed as et of further protocols to confirm thatthe hybridapproach of AdaptFlow offers adequate user supportf or the application of different protocols.Inathirdstep we analyzed real patientdatarecords to get some evidencef or the practical usefulness of asystem such as AdaptFlow.
6.1R epresentationofProtocols
Forthe representation of the three test protocols we decidedtomodelthe different therapyc ycles as separatew orkflowsf or each protocol. These ares tarted from ac oordination workflowt hatc ontains the whole therapy process. Figure 5shows afragment of the coordination workflowf or the MEGA-CHOEPp rotocol, Figure 4afrag ment of aworkflow for the application of the firstc hemotherapy cycle. Thee xceptions containedi nt he protocols were modeled using triggers on the patientd atabase (see 5.1). Thosesignal the occurrence of events thatm ay constitutea ne xception.F urthermore,wedefinedrules representing the therapy-specifick nowledge about the appropriatetherapy modificationsfor each exception.
During the protocolr epresentation we encounteredsome difficulties:
• An appropriate representation of timedependent conditions is particularlyimportantf or medical therapies( e.g., to model the interval between twot herapy steps).Thereby complexdirectives occur such as "apply drug At hreet imesb ut onlyifall applicationscan be performed in thisw eek". As the temporalmodelof the workflowsystem of AdaptFlowdoes not directly supports uchs pecifications we hadt ou se workaroundsf or those cases whichm adet he workflowr epresentation morecomplex.
• Thev alidity of exceptionsm ay depend on the execution stateofaworkflowinstance. As this oftenmay not be derived directly from the workflowengine again the therapy process representation hasto be extended,e.g., with dummyactivities thatjustindicate aparticularposition in a workflowinstance.
6.2A nalysisofFurtherProtocols
With the experiences made duringthe representation of the sample protocols we analyzed furtherprotocols to check whetherthe AdaptFlowp rototype is restrictedt ot he three pre-selected protocols. We concentratedontreatment protocols fromthe field of oncology as theyoffer longrunning, sufficientlystructured andcomplex processes suitablef or the representation in workflow systems. Moreover,e xceptionsa re describedinthe protocols to justify the useof the AdaptFlowsystem. We consideredt he following additional protocols: three protocols for the treatment of non-Hodgkin lymphoma [33] [34] [35] and two protocols for the treatment of Hodgkin lymphoma [36, 37] . Allthese protocols contain chemotherapy cycles preceded,s eparated or followedbyexaminations anddocumentation steps. Thes teps of the different protocols differinthe following points:
• the typeofthe examinationsrespectively the parameters thatare raisedinanexamination, • the typeand dosageofthe applied drugs, • the conditions that have to be fulfilledto continue the therapy, • additional treatments,e .g.r adiotherapy, in some protocols depending on the type of disease. These differences do not addcomplexity to the representation of the protocols,a nd AdaptFlowi sa blet oh andle them well. Also, no morecomplex time constructs have been found thatcould limitthe presentability of aprotocol. The sameh olds for the exceptionsd escribedi nt he protocols. They differi nt he parameters that have to be evaluated for exception detection (thep arametersa re providedb ythe examination steps of the therapy) andt he thresholds that decide which modification hastobeapplied.Asthe rules used in AdaptFlowa re therapy-specific, theyhavetobeadjustedfor different treatment protocols anyway.H ence, the new protocols requiren oa dditional complexity of the rule representation.Afurtherd ifference between the protocols can be found w.r.t. the therapy modifications. Butnone of the protocols contains at herapy modification thati sn ot supported by AdaptFlow. Thus,a ll additional protocols checked can be represented in AdaptFloww ithout any difficulties.
6.3A nalysisofPatient Data Records
An analysiso fr eal patientd atar ecords at the municipalhospital "St.Georg"inLeipzigrevealed the usefulnessofasystem such as AdaptFlow in practical clinical oncology. We lookeda tp atients with the diagnosis lymphoma treated according to different protocols (e.g.R ICOVER [ 38] , HD10, HD11, HD12 [37] ). Thepatients have been selected at random.
Exceptionsleading to therapy modificationsoccurred for over 70% of the considered patients duringtherapy execution.Several documentedexceptionsw erebased on medical data such as toxicities, infections, diagnoses, or generalr atings. Others were relatedt oo rganizational or social factors. We verifiedthatAdaptFlowisabletodetect alltypesofexceptionsthathavebeen documentedinthe sample patientrecords.
On average, during at reatment of a single patient3.4 exceptionsleading to therapym odifications occurred.9 4% of these necessarytherapy modificationshavebeen describedi nt he therapy protocols and would therefore also have been derivedb y AdaptFlow.
Discussion
We conclude from the evaluation studies presented in section 6t hatasignificant number of therapy protocols from oncology andofexceptionscontainedinthe protocols can be modeled, detected andh andled in AdaptFlow. Thus,t he combined approach of adaptive workflowm anagementa nd decision supportoffersadequate supportfor the application of guideline-based treatment protocols althought here ares ome exceptionsthatmay not be handled in AdaptFlow. Fori nstance, the detection of exceptions thath aveab roads cope of discretion may not be automatedi nAdaptFlow. Thes ame holds for exceptionsthatare based on very complexs ituationst hatn eed massive user interaction fore valuation.H owever,t hese types of exceptionso nlym akeu pasmall fraction of allexceptionsthatare described in the treatment protocol. Thus, it does not reducet he advantageso ft he AdaptFlow system significantly.
Furthermore,d ue to modificationsp erformedb ye arlierw orkflow adaptationsa n automatic derivation of the modifications for the next exceptionsm ay become impossibleasthe structure of the workflowinstance haschangedsignificantly. So,itdoes not correspond anymoretothe structure assumedbythe rules. Nevertheless, the exceptionscan still be detected automatically and the user can be informed. Thus,o ne main part of the AdaptFlowf unctionality is still availableand the system is valuablefor the further execution of this particularw orkflow instance.
Limitationsf or the workflowr epresentation mainlyo ccurred w.r.t. the limitation of existing workflowsystems to model complext ime constructs whicha re typical for therapy protocols. Thus,a ne nhanced time model would facilitate the workflowrepresentation of the therapy processes.
At the moment, the necessaryd ataf or exception detection,e.g., laboratoryv alues or diagnoses, is enteredmanuallyinAdaptFlow.Asweneed severalparametersthatare not directly availablef rom existing data sources such as clinical information or laboratorysystems buthavetobederived manuallyanyway(such as toxicity degrees),this additional effortf or the user is acceptable. Furthermore,i ntegrating hospitali nformation systemsw ith external applicationsi sa ssociated with severald ifficultiesa nd high costsa se .g.d escribedi n [39] [40] [41] . This integration is notaddressed by the AdaptFlowprototype.
Conclusions and Further Work
TheAdaptFlowprototype describedinthis papero fferse fficient supportf or the handling of complextrialtherapy processes by combining aworkflow management system with mechanisms forr ule-based dynamic workflowa daptation. AdaptFlowo bserves the status of the therapies currentlyb eing applied,o ffersa utomatic detection of exceptional situationsa nd appropriated ecision supportaswellasautomatic adaptation of affected therapy processes.Thus,AdaptFlow representsanenhancementofconsultation systemstofacilitate treatment application forthe medical staffand to increase treatment quality by enhancing the protocol conformanceofthe applied treatments.The AdaptFlowp rototype is therefore part of a broaderstrategy whichcurrentlyfocuses on the introduction of consultation systemsto supportstandardtreatment processes.Ithas been fullyi mplementeda nd af irste valuation hasbeen performed. Apractical useis envisioneda sas econd step of the overall strategy afterconsultation systems(such as OncoWorkstation [3]) have been widely adopted.
Futurew ork will investigatec ertain aspectso fw orkflow modeling fort reatment protocols in moredetail, especially modeling of temporalinformation such as activity execution durations. Furthermore,the optimald egreeo fa bstraction form odeling treatment protocols hast ob ee xplored.I n this context, treatment protocols fromother medical domains will also be taken into account.
